Genesis Drug Discovery & Development, a provider of services to help preclinical drug development programs, completed the acquisition of JSS Medical Research, a full-service clinical research organization. Financial terms were not disclosed. "The single most important factor that drove our decision to accept Genesis Global Group's acquisition offer for JSS Medical Research was that, similarly to JSS, GD3 has its origin rooted in science, and it is an organization committed to scientific excellence. Both GD3 and JSS have science as their core foundation. The merger of the two companies creates an organization that will deliver state-of-the-art scientific support and services to our combined and growing list of pharmaceutical, biotechnology and medical device clients," John S. Sampalis, JSS Medical Research Chief Executive Officer and Chief Scientific Officer.